GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
  • Education
    • Master Theses
    • PhD Theses
  • Services
Home / Archives for Cuypers L

Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning

  • Autores: Ceccherini-Silberstein F, Cento V, Cuypers L, Di Maio VC, Libin P, Lunar MM, Nevens F, Nowé A, Poljak M, Schrooten Y, Theys K, Van Laethem K, Vandamme AM
  • Ano de Publicação: 2017
  • Journal: Infection Genetics and Evolution
  • Link: https://www.sciencedirect.com/science/article/pii/S1567134817301582?via%3Dihub

Resistance-associated variants (RAVs) have been shown to influence treatment response to direct-acting antivirals (DAAs) and first generation NS3/4A protease inhibitors (PIs) in particular. Interpretation of hepatitis C virus (HCV) genotypic drug resistance remains a challenge, especially in patients who previously failed DAA therapy and need to be retreated with a second DAA based regimen. Bayesian […]
Ler mais

Zika virus genetic diversity and selective pressure: importance for diagnostics, vaccines and therapeutics

  • Autores: Abecasis A, Cuypers L, Libin P, Theys K, Vandamme AM
  • Ano de Publicação: 2017
  • Journal: Tropical Medicine & International Health

During the last years, an increasing number of Zika virus (ZIKV) infections has been reported in Asia and America. Due to socio-environmental factors that remain to be established, this arbovirus has explosively spread to more than 60 countries worldwide. ZIKV infections can result into severe clinical manifestations, with little knowledge available to date about how […]
Ler mais

HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial

  • Autores: Crabbe R, Cuypers L, Kerremans L, Libin P, Snoeck J, Van Dooren S, Vandamme AM, Vuagniaux G
  • Ano de Publicação: 2016
  • Journal: Infection Genetics and Evolution
  • Link: https://www.sciencedirect.com/science/article/pii/S156713481630274X?via%3Dihub

Major advances have revolutionized the HCV antiviral treatment field, with interferon-free combinations of direct-acting antivirals (DAAs) resulting into success rates of >90% for all HCV genotypes. Nevertheless, viral eradication at a global level stills remains challenging, stimulating the continued search for new affordable pan-genotypic drugs. To overcome selection of drug resistant variants, targeting host proteins […]
Ler mais

A near-full length genotypic assay for HCV1b

  • Autores: Camacho RJ, Cuypers L, Kerremans L, Nevens F, Snoeck J, Van Dooren S, Vandamme AM, Verbeeck J, Vrancken B, Vuagniaux G
  • Ano de Publicação: 2014
  • Journal: Journal of Virological Methods
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25245140

A near-full genome genotypic assay for HCV1b was developed, which may prove useful to investigate antiviral drug resistance, given new combination therapies for HCV1 infection. The assay consists of three partially overlapping PCRs followed by Sanger population or Illumina next-generation sequencing.
Ler mais

  • « Previous Page
  • 1
  • 2

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013